Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Gastroenterology
Published in: BMC Gastroenterology 1/2020

Open Access 01-12-2020 | Acute Pancreatitis | Research article

Increased circulating total bile acid levels were associated with organ failure in patients with acute pancreatitis

Authors: Xiaochun Xie, Jie Dong, Guotao Lu, Kun Gao, Xiaoyao Li, Wenjian Mao, Faxi Chen, Zhihui Tong, Baiqiang Li, Weiqin Li

Published in: BMC Gastroenterology | Issue 1/2020

Login to get access

Abstract

Background

Recent studies have shown that bile acids (BAs) are closely related to metabolic and inflammatory diseases. Our study aimed to investigate whether circulating total bile acid (TBA) levels were associated with the severity of acute pancreatitis (AP).

Methods

We retrospectively collected data on patients diagnosed with AP in a tertiary center from 01 January 2014 to 31 December 2016. The highest TBA value during the first 1,2,3,5,7 days after admission was determined as D1, D2, D3, D5, D7 TBAmax. Patients were divided into the high TBA (HTBA) group and the normal TBA (NTBA) group according to whether the TBAmax was ≥10 μmol/L. The prognosis and complications, including death, organ failure (OF) and pancreatic necrosis, were compared between the two groups. Logistic regression analysis and receiving operating characteristic (ROC) curve were used to evaluate the relationship between circulating TBA and organ failure in AP patients.

Results

Through stratified analysis of each time period, we found that the incidence of OF in the HTBA group was significantly higher than that in the NTBA group, and the AP severity classification in the HTBA group was more serious than that in the NTBA group. In addition, according to the D7 TBAmax values, the pancreatic necrosis rate, percutaneous catheter drainage (PCD) rate and mortality in the HTBA group were higher than those in the NTBA group. Multivariate regression analysis showed that HTBA (odds ratio (OR), 4.894; P = 0.002) was an independent risk factor for AP complicated with OF, which was verified in the grouping based on D7 TBAmax. ROC analysis revealed that a circulating D7 TBAmax cutoff point of 6.450 umol/L had optimal predictive value for the development of OF in AP patients with an area under the curve of the ROC curve (AUCROC) of 0.777.

Conclusions

The increase of circulating TBA in early stage of AP is independently related to organ failure, which indicates the adverse prognosis of AP patients.
Appendix
Available only for authorised users
Literature
1.
2.
Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143(5):1179–87.e3.PubMedPubMedCentralCrossRef
3.
Tenner S, Baillie J, DeWitt J, Vege SS. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108(9):1400–15 16.PubMedCrossRef
4.
Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006;101(10):2379–400.PubMedCrossRef
5.
Babu RY, Gupta R, Kang M, Bhasin DK, Rana SS, Singh R. Predictors of surgery in patients with severe acute pancreatitis managed by the step-up approach. Ann Surg. 2013;257(4):737–50.PubMedCrossRef
6.
Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62(1):102–11.PubMedCrossRef
7.
8.
Fuchs C, Claudel T, Trauner M. Bile acid-mediated control of liver triglycerides. Semin Liver Dis. 2013;33(4):330–42.PubMedCrossRef
9.
10.
McGlone ER, Bloom SR. ANNALS EXPRESS: Bile acids and the metabolic syndrome. Ann Clin Biochem. 2019;56(3):326–37.
11.
Han CY. Update on FXR Biology: Promising Therapeutic Target? Int J Mol Sci. 2018;19(7):2069.
12.
Xie Y, He Y, Cai Z, Cai J, Xi M, Zhang Y, et al. Tauroursodeoxycholic acid inhibits endoplasmic reticulum stress, blocks mitochondrial permeability transition pore opening, and suppresses reperfusion injury through GSK-3ss in cardiac H9c2 cells. Am J Transl Res. 2016;8(11):4586–97.PubMedPubMedCentral
13.
Cummings BP, Bettaieb A, Graham JL, Kim J, Ma F, Shibata N, et al. Bile-acid-mediated decrease in endoplasmic reticulum stress: a potential contributor to the metabolic benefits of ileal interposition surgery in UCD-T2DM rats. Dis Model Mech. 2013;6(2):443–56.PubMedCrossRef
14.
Trauner M, Claudel T, Fickert P, Moustafa T, Wagner M. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis. 2010;28(1):220–4.PubMedCrossRef
15.
Maleszka A, Dumnicka P, Matuszyk A, Pedziwiatr M, Mazur-Laskowska M, Sporek M, et al. The Diagnostic Usefulness of Serum Total Bile Acid Concentrations in the Early Phase of Acute Pancreatitis of Varied Etiologies. Int J Mol Sci. 2017;18(1):106.
16.
17.
Haeusler RA, Camastra S, Nannipieri M, Astiarraga B, Castro-Perez J, Xie D, et al. Increased bile acid synthesis and impaired bile acid transport in human obesity. J Clin Endocrinol Metab. 2016;101(5):1935–44.PubMedCrossRef
18.
Sonne DP, van Nierop FS, Kulik W, Soeters MR, Vilsboll T, Knop FK. Postprandial plasma concentrations of individual bile acids and FGF-19 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2016;101(8):3002–9.PubMedCrossRef
19.
Wewalka M, Patti ME, Barbato C, Houten SM, Goldfine AB. Fasting serum taurine-conjugated bile acids are elevated in type 2 diabetes and do not change with intensification of insulin. J Clin Endocrinol Metab. 2014;99(4):1442–51.PubMedPubMedCentralCrossRef
20.
Sun W, Zhang D, Wang Z, Sun J, Xu B, Chen Y, et al. Insulin resistance is associated with Total bile acid level in type 2 diabetic and nondiabetic population: a cross-sectional study. Medicine. 2016;95(10):e2778.PubMedPubMedCentralCrossRef
21.
Dellinger EP, Forsmark CE, Layer P, Levy P, Maravi-Poma E, Petrov MS, et al. Determinant-based classification of acute pancreatitis severity: an international multidisciplinary consultation. Ann Surg. 2012;256(6):875–80.PubMedCrossRef
22.
Petrov MS, Windsor JA. Conceptual framework for classifying the severity of acute pancreatitis. Clin Res Hepatol Gastroenterol. 2012;36(4):341–4.PubMedCrossRef
23.
Hennekens CH, DeMets D. Statistical association and causation: contributions of different types of evidence. Jama. 2011;305(11):1134–5.PubMedCrossRef
24.
Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology. 2013;13(4 Suppl 2):e1–15.
25.
Mofidi R, Duff MD, Wigmore SJ, Madhavan KK, Garden OJ, Parks RW. Association between early systemic inflammatory response, severity of multiorgan dysfunction and death in acute pancreatitis. Br J Surg. 2006;93(6):738–44.PubMedCrossRef
26.
Singh VK, Wu BU, Bollen TL, Repas K, Maurer R, Mortele KJ, et al. Early systemic inflammatory response syndrome is associated with severe acute pancreatitis. Clin Gastroenterol Hepatol. 2009;7(11):1247–51.PubMedCrossRef
27.
Garg PK, Singh VP. Organ Failure due to Systemic Injury in Acute Pancreatitis. Gastroenterol. 2019;156(7):2008–23.CrossRef
28.
Parniczky A, Kui B, Szentesi A, Balazs A, Szucs A, Mosztbacher D, et al. Prospective, multicentre, Nationwide clinical data from 600 cases of acute pancreatitis. PLoS One. 2016;11(10):e0165309.PubMedPubMedCentralCrossRef
29.
Sathyanarayan G, Garg PK, Prasad H, Tandon RK. Elevated level of interleukin-6 predicts organ failure and severe disease in patients with acute pancreatitis. J Gastroenterol Hepatol. 2007;22(4):550–4.PubMedCrossRef
30.
Whitcomb DC, Muddana V, Langmead CJ, Houghton FD Jr, Guenther A, Eagon PK, et al. Angiopoietin-2, a regulator of vascular permeability in inflammation, is associated with persistent organ failure in patients with acute pancreatitis from the United States and Germany. Am J Gastroenterol. 2010;105(10):2287–92.PubMedCrossRef
31.
Kolber W, Kusnierz-Cabala B, Dumnicka P, Maraj M, Mazur-Laskowska M, Pedziwiatr M, et al. Serum Urokinase-Type Plasminogen Activator Receptor Does Not Outperform C-Reactive Protein and Procalcitonin as an Early Marker of Severity of Acute Pancreatitis. J Clin Med. 2018;7(10):305.
32.
Chiang JY. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr Rev. 2002;23(4):443–63.PubMedCrossRef
33.
34.
Luo L, Aubrecht J, Li D, Warner RL, Johnson KJ, Kenny J, et al. Assessment of serum bile acid profiles as biomarkers of liver injury and liver disease in humans. PLoS One. 2018;13(3):e0193824.PubMedPubMedCentralCrossRef
35.
Bayerdorffer E, Mannes GA, Ochsenkuhn T, Dirschedl P, Wiebecke B, Paumgartner G. Unconjugated secondary bile acids in the serum of patients with colorectal adenomas. Gut. 1995;36(2):268–73.PubMedPubMedCentralCrossRef
36.
Costarelli V, Key TJ, Appleby PN, Allen DS, Fentiman IS, Sanders TA. A prospective study of serum bile acid concentrations and colorectal cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer. 2002;86(11):1741–4.PubMedPubMedCentralCrossRef
37.
Feng HY, Chen YC. Role of bile acids in carcinogenesis of pancreatic cancer: an old topic with new perspective. World J Gastroenterol. 2016;22(33):7463–77.PubMedPubMedCentralCrossRef
38.
Hao H, Cao L, Jiang C, Che Y, Zhang S, Takahashi S, et al. Farnesoid X Receptor Regulation of the NLRP3 Inflammasome Underlies Cholestasis-Associated Sepsis. Cell Metab. 2017;25(4):856–67.e5.PubMedPubMedCentralCrossRef
39.
Garcia-Irigoyen O, Moschetta A. A novel protective role for FXR against Inflammasome activation and Endotoxemia. Cell Metab. 2017;25(4):763–4.PubMedCrossRef
40.
Iracheta-Vellve A, Calenda CD, Petrasek J, Ambade A, Kodys K, Adorini L, et al. FXR and TGR5 agonists ameliorate liver injury, Steatosis, and inflammation after binge or prolonged alcohol feeding in mice. Hepatol Commun. 2018;2(11):1379–91.PubMedPubMedCentralCrossRef
41.
Cipriani S, Mencarelli A, Chini MG, Distrutti E, Renga B, Bifulco G, et al. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS One. 2011;6(10):e25637.PubMedPubMedCentralCrossRef
42.
Zhou X, Xie L, Bergmann F, Endris V, Strobel O, Buchler MW, et al. The bile acid receptor FXR attenuates acinar cell autophagy in chronic pancreatitis. Cell Death Dis. 2017;3:17027.CrossRef
43.
Li B, Yang N, Li C, Li C, Gao K, Xie X, et al. INT-777, a bile acid receptor agonist, extenuates pancreatic acinar cells necrosis in a mouse model of acute pancreatitis. Biochem Biophys Res Commun. 2018;503(1):38–44.PubMedCrossRef
Metadata
Title
Increased circulating total bile acid levels were associated with organ failure in patients with acute pancreatitis
Authors
Xiaochun Xie
Jie Dong
Guotao Lu
Kun Gao
Xiaoyao Li
Wenjian Mao
Faxi Chen
Zhihui Tong
Baiqiang Li
Weiqin Li
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2020
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-020-01243-w

Other articles of this Issue 1/2020

BMC Gastroenterology 1/2020 Go to the issue

Research article

Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review

Research article

Combined effects of lifestyle risk factors on fatty liver index

Case report

Juvenile polyposis syndrome might be misdiagnosed as familial adenomatous polyposis: a case report and literature review

Research article

Eosinophilic gastroenteritis as a cause of non-Helicobacter pylori, non-gastrotoxic drug ulcers in children

Research article

The relationship between preoperative T helper cytokines in the ileal mucosa and the pathogenesis of pouchitis

Research article

Non-alcoholic fatty liver disease among patients with sleep disorders: a Nationwide study of Taiwan
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits